Abstract: A test capsule for measuring at least one property of a material exposed to nuclear radiation comprises a lattice structure configured to exhibit a change in at least one property responsive to exposure to nuclear radiation. The lattice structure comprises a first strut and a second strut connected to the first strut at a node. Related test capsules and methods are also described.

Abstract: 3D MRI images of the brain may be created and acquired. After administration of contrast, brain lesions and other abnormalities may be identified and isolated from the 3D MRI images, with each lesion serving as a region of interest (ROI). 3D region of contrast enhancement images may be created from segmented 3D MRI images and different regions of contrast enhancement of the brain lesion may be depicted. Saved regions of contrast enhancement may be converted into stereolithography format, maximum intensity projection (MIP) images, and/or orthographic projection images. Data corresponding to these resulting 3D region of contrast enhancement images may be used to create 3D printed models of the isolated region of contrast enhancement. Analysis of the 3D brain region of contrast enhancement images and the 3D printed region of contrast enhancement models may enable a more efficient and accurate way of determining brain lesion risk factors and effective treatment regimens.

Abstract: Provided are methods for sequential radiotherapies, such as XRT. In some embodiments, a higher dosage of an XRT may first be administered to a subject, optionally in combination with an immunotherapy, and subsequently a lower dosage XRT is administered to the subject to treat a cancer. Separating the dosage and intensity of the radiotherapies can be used to achieve improved therapeutic responses, such as improved anti-cancer responses, survival times, and/or abscopal effects.

Abstract: The present disclosure provides ?2?-1 C-terminal domain mimetics for the treatment of pain, epilepsy or other disorders in a subject. Further provided is an ?2?-1 C-terminal domain peptide which blocks binding of ?2?-1 to the glutamate receptors NMDAR and AMPAR.

Abstract: Devices and methods for extraction and processing of substantia gelatinea funiculi umbilicalis (Wharton's Jelly) from an umbilical cord.

Abstract: Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.

Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind SLC45A2. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.

Abstract: Provided herein are LILRB4-binding antibodies and methods of treating cancer by administering the LILRB4-binding antibodies alone or in combination with other therapies. Recombinant polypeptides comprising the CDRs of LILRB4-binding antibodies are also provided.

Abstract: The present invention relates to the treatment of secretory disorders, and provides novel methods of treatment of these disorders comprising the administration of fibroblast growth factor 21 (FGF21) or derivatives thereof. The methods of the invention are useful in conditions including exocrine pancreatic insufficiency (EPI), for example EPI resulting from cystic fibrosis, alcoholism, pancreatitis, pancreatic cancer, gallstones, celiac disease, high triglycerides, or lupus. The methods of the present invention find further utility in the treatment of salivary flow disorders, for example Sjorgen's syndrome, and the treatment of EPI or pancreatitis resulting from surgical procedures.

Abstract: Disclosed herein are methods of treatments with a telomerase-mediated telomere-targeting drug, 6-thio-2?-deoxyguanosine (6-thio-dG), checkpoint inhibitors and/or radiation therapy for treating cancers. eads to tumor regression in innate and adaptive immune-dependent manners in syngeneic and humanized mouse cancer models.

Abstract: Methods and systems for computer-assisted contour revision. An image slice may be selected from a medical image. The image slice may include an initial contour of a target anatomical structure in the medical image. At least a portion of the image slice and the initial contour may be displayed on a graphical user interface (GUI). Upon determining that the initial contour requires revision, a revised contour may be generated. A first input may be received from a user to the GUI to indicate a first point of revision. The medical image, the first input, and the initial contour may be input into a trained deep neural network that automatically extracts learned image characteristics. The extracted learned image characteristics may be processed using one or more deep-learning segmentation algorithms of the trained deep neural network. The revised contour may be automatically generated using the processed extracted learned image characteristics.

Abstract: Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of a TLR agonist and a chimeric CD154 polypeptide. Also provided herein are methods of enhanced immune function.

Abstract: An elongate, flexible, medical device having distal and proximal ends, including an inner member having a proximal and distal end, a support member extending around the inner member between the proximal and distal end, a plurality of electrically-conductive wires, each braided with the support member having a proximal and distal end, an outer member surrounding the inner member, the support member, and the plurality of electrically-conductive wires and an actuator including a polymer electrolyte layer secured adjacent to the distal end of the elongate, flexible inner member and defining an exterior surface, electrodes distributed about the exterior of the polymer electrolyte layer. The distal end of one of the electrically-conductive wires is electrically connected to one of the electrodes. The polymer electrolyte layer is configured to deform asymmetrically in response to the application of an electrical signal through the plurality of electrically-conductive wires to the plurality of electrodes.

Abstract: Methods for treating, reducing, ameliorating or inhibiting symptoms idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia, comprising administering to a subject in need of an effective amount of a) multiple EGF-like-domains-9 (MEGF9) or a biologically active fragment thereof; b) uncoordinated receptor 5A (UNC5A) or a biologically active fragment thereof; c) dolichyl-phosphate beta-glucosyltransferase (ALG5) or a biologically active fragment thereof; d) a combination of two or three of a)-c); e) an antibody specifically binding to a); f) an antibody specifically binding to b); g) an antibody specifically binding to c); h) a combination of two or three of e)-g); or i) a combination of at least one of a)-c) and at least one of e)-g). Pharmaceutical compositions and processes for making and using the compositions are also disclosed.

Abstract: In fibrotic lung fibroblasts, basal levels of p53 protein (and miR-34a) are markedly suppressed, leading to reduced p53-mediated inhibition of uPA and uPAR, or concurrent induction of PAI-1. These changes contribute to excessive FL-fibroblast proliferation and production of extracellular matrix (ECM), and, therefore, pulmonary fibrosis. These processes are reversed by treating the cells, and treating subjects suffering from idiopathic pulmonary fibrosis (IPF) with the small organic molecule nutlin-3a (NTL) or with a peptide, CSP-4 (SEQ ID NO:1), or variants or derivatives or multimers of this peptide, which increase p53 levels by inhibiting MDM2-mediated degradation of p53 protein. Use of these compounds serves as a new approach to the treatment of IPF, as they restore p53 expression and p53-mediated changes in the uPA-fibrinolytic system in FL-fibroblasts and restrict production and deposition of ECM.

Abstract: Provided herein are phosphorylated Dicer 1 (pDicer1) antibodies, including those that selectively bind Serine 1728 and/or Serine 1852. Further provided herein are methods of treating cancer by administering the pDicer1 antibodies alone or in combination with other therapies.

Abstract: The present disclosure provides methods for re-programming effector T cells to a central memory phenotype comprising culturing the effector T cells with a histone deacetylase inhibitor (HDACi) and IL-21. Further provided are methods of treating cancer comprising administering the central memory T cells.

Abstract: The inventor has discovered that limiting mitochondrial Mg2+ uptake (mMg2+) prevents diet-induced obesity. Administration of compositions that limit mitochondrial Mg2+ uptake (mMg2+) can be used for various therapeutic and prophylactic uses.

Abstract: Disclosed herein are embodiments of methods for preparing aminated or alkylaminated CNTs wherein the aminated or alkylaminated CNTs are obtained in a reaction by reacting the CNTs with an aminating or alkylaminating reagent in a non-hazardous solvent or a non-hazardous solvent-deionized water mixture. The CNTs may be single-walled, double-walled or multi-walled CNTs. The disclosed processes for amination and alkylamination do not require treatment with concentrated acid, and with the use of solvent, the CNTs and aminating compound or alkylaminating compound are mixed thoroughly throughout the reaction.